Resilience After Paralysis Inc.

04/22/2026

This organization hosts some amazing events. Please check them out. 

02/18/2026

02/18/2026

https://www.facebook.com/share/1FnrkauUDQ/?mibextid=wwXIfr

NuMotion will host clinics at Turnstone on the 1st and 3rd Tuesday of the month and the 2nd and 4th Thursday of the month from 8 AM-4 PM. Services provided will include equipment inspections, functional/positioning assessments, new order placements, equipment adjustments, and repair inquiries.

In February, clinics will be held on Thursday, Feb. 12; Tuesday, Feb. 17; and Thursday, Feb. 26.

Attendees should ask for Josh with NuMotion at the Peds Therapy OR Plassman Athletic Center front desks during scheduled clinic days. It is first come, first serve so there may be a wait. This clinic is intended to empower and improve the lives of people with disabilities. For more information, please contact Ryan Grimes at [email protected].

02/12/2026

https://www.facebook.com/share/p/16YQh11dhN/?mibextid=wwXIfr

A breakthrough drug made from placental protein is moving to human trials.

And it has the potential to reverse paralysis and regenerate spinal cord connections.

Developed by researchers at the Federal University of Rio de Janeiro (UFRJ) in partnership with the Cristália laboratory, Polylaminin represents a significant leap in regenerative medicine. This experimental drug, synthesized from placental proteins, is designed to be injected directly into the site of a spinal cord injury via a minimally invasive procedure. Unlike traditional treatments that focus on stabilizing damage, Polylaminin actively stimulates the growth of new axons and encourages the reconstruction of vital neural pathways, offering a biological bridge where connections were previously severed.

As of early 2026, Brazil’s health regulatory agency, Anvisa, has officially authorized the first stage of human clinical trials to evaluate the drug's safety in patients with complete spinal cord injuries. Early-stage reports have been remarkably optimistic, suggesting that some individuals with paraplegia and quadriplegia regained motor function and sensory perception during preliminary observations. While the medical community remains cautiously optimistic, further rigorous peer-reviewed testing and larger clinical trials are essential before this revolutionary therapy can be approved for widespread clinical use.

source: Coelho-Sampaio, T., & Federal University of Rio de Janeiro. (2026). Polylaminin and Neural Regeneration: Results from Phase 1 Regulatory Approval. Folha de S.Paulo.

02/07/2026

https://news.feinberg.northwestern.edu/2025/07/23/dancing-molecules-treatment-receives-fda-orphan-drug-designation/

“Dancing molecules,” a promising new treatment for acute spinal cord injuries developed at Northwestern University, has received Orphan Drug Designation from the U.S. Food and Drug Administration.

02/03/2026

The RSVP link is in the comments section below. 

12/29/2025

Our upcoming meetings are going to be January 3rd, February 7th, March 7th, and April 4th, at Parkview Randallia from 11-1!

Contact Ryan if you need further details.
Tel 260.206.3983 

12/20/2025

https://www.facebook.com/share/1BxfXfdtDJ/?mibextid=wwXIfr

American scientists discovered drug reversing paralysis in injured patients 💊
Researchers at Northwestern University just achieved something neurologists considered impossible—they've developed an injectable drug that repairs severed spinal cords and reverses paralysis in patients injured years ago. In clinical trials, four patients paralyzed from the waist down for 2-8 years regained significant movement and sensation within months of treatment. This isn't incremental improvement; this is paralyzed patients standing, walking with assistance, and regaining bowel and bladder control. The drug doesn't just prevent further damage—it actively reverses spinal cord injuries by regrowing damaged neural pathways that everyone believed were permanently destroyed.
The breakthrough involves synthetic molecules that self-assemble into nanofiber scaffolds when injected directly into the injury site. These scaffolds mimic the spinal cord's natural structure, providing a framework for nerve cells to grow along. The nanofibers are coated with signals that tell neurons "grow this direction" while blocking inflammatory responses that normally create scar tissue preventing regeneration. Simultaneously, the drug delivers compounds that activate dormant neural stem cells and encourage them to develop into new neurons and support cells. It's like providing both the construction materials and the blueprints for the spinal cord to rebuild itself.
Over 300,000 Americans live with spinal cord injuries, and 17,000 new cases occur annually—mostly from car accidents, falls, and sports injuries. Current treatment offers only damage control, not recovery. This drug changes paralysis from a permanent sentence to a treatable condition. Beyond spinal injuries, the same approach shows promise for stroke recovery, traumatic brain injuries, and degenerative nerve diseases. For millions living with paralysis, this represents hope where none existed before.
The drug's effects appear within weeks—patients first regain sensation, then muscle twitches, then voluntary movement gradually strengthens. Treatment costs about $120,000 currently but works on injuries years old, meaning anyone paralyzed could potentially benefit. FDA approval is expected in late 2026. If nerves can be convinced to regrow after years of damage, what other "permanent" conditions might actually be reversible?
Source: Northwestern University Feinberg School of Medicine, Science Translational

12/20/2025

https://m.facebook.com/story.php?story_fbid=711247352056930&id=100095150140681&mibextid=wwXIfr

Paralyzed patients in Seoul are walking again thanks to revolutionary embryonic stem cell therapy developed at Seoul National University.

Specialized neural stem cells are injected directly into the injury site, differentiating into neurons and support cells that bridge damaged spinal cord tissue. Over 6–12 months, patients regain motor control and sensation, confirmed by MRI scans showing real nerve regeneration.

U.S. clinical trials remain stalled due to ethical controversies and bureaucratic delays. Only limited Phase I safety trials are approved, leaving thousands of Americans with spinal cord injuries without effective treatment.

Some desperate patients travel to Seoul, spending over $150,000 to access therapy unavailable at home. The question remains: should politics condemn Americans to permanent paralysis?

Bottom Fact: South Korea’s stem cell therapy has restored movement in 67 previously paralyzed patients, while U.S. trials are stalled in ethical and bureaucratic delays.

Source: Seoul National University, Spinal Cord Regeneration Institute 2024

Disclaimer: Shared for informational purposes only. Not medical advice. Consult a healthcare professional for spinal cord injury treatment.